Advertisement

Embelin Ameliorate Testosterone-Induced Prostatic Hyperplasia in Rats

  • Marulasiddeshwara Roopesh
  • S. R. Anand Kumar
  • Shivsharan B. Dhadde
  • B. S. Thippeswamy
  • Veeresh P. Veerapur
  • S. Badami
  • N. C. K. Baburao
Research Article
  • 50 Downloads

Abstract

Embelin, is a naturally occurring alkyl substituted hydroxyl benzoquinone and a major constituent from all the parts of Embelia ribes. It possesses antitumor, anti-inflammatory, antioxidant, analgesic activities and also has the ability to decrease testosterone levels. The present study was designed to determine the effect of embelin on testosterone-induced benign prostatic hyperplasia (BPH) in rats. Male Wistar rats were randomly divided into six groups and treated with either embelin (5 and 10 mg/kg), finasteride (1 mg/kg) or vehicle. After above mentioned treatment, testosterone (3 mg/kg; subcutaneously) was administration for 28 days, to induce BPH. On the day 29, blood samples were collected from the retro-orbital plexus. After blood sample collection, animals were sacrificed and prostates were immediately dissected out for weight measurement, biochemical estimations and histopathological studies. Prostatic serum acid phosphatase (PSAP) and prostate-specific antigen (PSA) were estimated. Administration of testosterone leads to significant increase in prosthetic weight, PSAP, PSA and lipid peroxidation levels and decrease in the antioxidant status. Moreover, histopathological abnormalities in the prostatic tissue were also found in these animals. Treatment with both the doses of embelin and finasteride significantly reversed the changes produced by testosterone. The authors conclude that antioxidant and anti-inflammatory properties of embelin are responsible for its protection against testosterone-induced BPH.

Keywords

Embelia ribes Antioxidant Prostatic serum acid phosphatase Prostate-specific antigen 

References

  1. 1.
    Untergasser G, Madersbacher S, Berger P (2005) Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol 40:121–128CrossRefPubMedGoogle Scholar
  2. 2.
    Irani J, Brown CT, van der Meulen J, Emberton M (2003) A review of guidelines on benign prostatic hyperplasia and lower urinary tract symptoms: are all guidelines the same? BJU Int 92:937–942CrossRefPubMedGoogle Scholar
  3. 3.
    Bartsch G, Rittmaster RS, Klocker H (2000) Dihydrotestosterone and 5-alpha reductase inhibition in human benign prostatic hyperplasia. Eur Urol 37:367–380CrossRefPubMedGoogle Scholar
  4. 4.
    Carson C, Rittmaster R (2003) The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61:2–7CrossRefPubMedGoogle Scholar
  5. 5.
    Thompson TC, Yang G (2000) Regulation of apoptosis in prostatic disease. Prostate Suppl 9:25–28CrossRefPubMedGoogle Scholar
  6. 6.
    Belostotskaia LI, Nikitchenko IV, Gomon N, Chaika LA, Bondar VV, Dziuba VN (2006) Effect of biologically active substances of animal and plant origin on prooxidant–antioxidant balance in rats with experimental prostatic hyperplasia. Eksp Klin Farmakol 69:66–68PubMedGoogle Scholar
  7. 7.
    Liu CC, Huang SP, Li WM, Wang CJ, Chou YH, Li CC, Huang CH, Wu WJ (2007) Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men. Urology 70:677–680CrossRefPubMedGoogle Scholar
  8. 8.
    Michel MC, Taguchi K, Schafers RS, Schafers RS, Williams TJ, Clarke DE, Ford AP (1998) α 1-adrenoceptors subtype in humans cardiovascular and urogenital system. Adv Pharmacol 42:394–398CrossRefPubMedGoogle Scholar
  9. 9.
    Patel AK, Chapple CR (2008) Benign prostatic hyperplasia: treatment in primary health care. BMJ 333:535–539CrossRefGoogle Scholar
  10. 10.
    Plosker GL, Brogden RN (1996) Serenoarepens (Permixon). A review of its pharmacological and therapeutic efficacy in benign prostatic hyperplasia. Drug Aging 9:379–395CrossRefGoogle Scholar
  11. 11.
    Arruzabala ML, Molina V, Mas R, Carbajal D, Marrero D, Gonzalez V, Rodriguez E (2006) Effect of coconut oil on testosterone-induced prostatic hyperplasia in Sprague Dawley rats. J Pharm Pharmacol 59:995–999CrossRefGoogle Scholar
  12. 12.
    In-Sik S, Mee-Young L, Da-Young J, Chang-Seob S, Hye-Kyung H, Hyeun-Kyoo S (2012) Ursolic acid reduces prostate size and dihydrotestosterone level in a rat model of benign prostatic hyperplasia. Food Chem Toxicol 50:884–888CrossRefGoogle Scholar
  13. 13.
    Mahendran S, Maithili V, Badami S (2011) Evaluation of antidiabetic effect of embelin from Embelia ribes in alloxan induced diabetes in rats. Biomed Prev Nutr 1:25–31CrossRefGoogle Scholar
  14. 14.
    Chitra M, Sukumar E, Suja V, Devi CSS (1994) Antitumor, anti-inflammatory and analgesic property of embelin, a plant product. Chemotherapy 40:109–113CrossRefPubMedGoogle Scholar
  15. 15.
    Thippeswamy BS, Nagakannan P, Shivasharan BD, Mahendran S, Veerapur VP, Badami S (2011) Protective effect of embelin from Embelia ribes Burm. against transient global ischemia induced brain damage in rats. Neurotox Res 20:379–386CrossRefPubMedGoogle Scholar
  16. 16.
    Dhadde SB, Nagakannan P, Roopesh M, Anand Kumar SR, Thippeswamy BS, Veerapur VP, Badami S (2016) Effect of embelin against 3-nitropropionic acid-induced Huntington’s disease in rats. Biomed Pharmacother 77:52–58CrossRefPubMedGoogle Scholar
  17. 17.
    Shaikh A, Dhadde SB, Durg S, Veerapur VP, Badami S, Thippeswamy BS, Patil JS (2016) Effect of embelin against lipopolysaccharide-induced sickness behaviour in mice. Phytother Res 30:815–822CrossRefPubMedGoogle Scholar
  18. 18.
    Githui EK, Makawiti DW, Midiwo JO (1991) Changes in the concentrations of testosterone, luteinising hormone and progesterone associated with administration of embelin. Contraception 44:311–317CrossRefPubMedGoogle Scholar
  19. 19.
    Hu R, Zhu K, Li Y, Yao K, Zhang R, Wang H, Yang W, Liu Z (2011) Embelin induces apoptosis through down-regulation of XIAP in human leukemia cells. Med Oncol 28:1584–1588CrossRefPubMedGoogle Scholar
  20. 20.
    Vyas BA, Niket Y, Desai PK, Patel S, Joshi V, Dinesh R Shah (2013) Effect of Boerhaavia diffusa in experimental prostatic hyperplasia in rats. Indian J Pharmacol 45:264–269CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275PubMedGoogle Scholar
  22. 22.
    Gelvan D, Saltman P (1990) Different cellular targets of Cu- and Fe-catalyzed oxidation observed using a Cu-compatible thiobarbiturate acid assay. Biochim Biophys Acta 1035:353–360CrossRefPubMedGoogle Scholar
  23. 23.
    Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70–77CrossRefPubMedGoogle Scholar
  24. 24.
    Sedlak J, Lindsay R (1968) Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 25:192–205CrossRefPubMedGoogle Scholar
  25. 25.
    Claiborne A (1985) Handbook of methods for oxygen radical research. CRC Press, LondonGoogle Scholar
  26. 26.
    Ripple MO, William FH, Randall PR, George W (1997) Pro oxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 89:40–48CrossRefPubMedGoogle Scholar
  27. 27.
    Naslund MJ, Coffey DS (1986) The differential effects of neonatal androgens, estrogen and progesterone on adult rat prostate growth. J Urol 36:1136–1140CrossRefGoogle Scholar
  28. 28.
    Fujii J, Iuchi Y, Matsuki S, Ishii T (2003) Cooperative function of antioxidant and redox systems against oxidative stress in male reproductive tissues. Asian J Androl 5:231–242PubMedGoogle Scholar
  29. 29.
    Walter FB, Boulpaep EL, Medical Physiology (2003) A cellular and molecular approach. Saunders, PhiladelphiaGoogle Scholar

Copyright information

© The National Academy of Sciences, India 2017

Authors and Affiliations

  • Marulasiddeshwara Roopesh
    • 1
  • S. R. Anand Kumar
    • 1
  • Shivsharan B. Dhadde
    • 2
  • B. S. Thippeswamy
    • 3
  • Veeresh P. Veerapur
    • 1
  • S. Badami
    • 1
  • N. C. K. Baburao
    • 2
  1. 1.Sree Siddaganga College of PharmacyTumkurIndia
  2. 2.D.S.T.S. Mandal’s College of PharmacySolapurIndia
  3. 3.Department of Biomedical Science, College of PharmacyShaqra UniversityAl-DawadmiKingdom of Saudi Arabia

Personalised recommendations